BiomX (PHGE) Registration Filing summary

Company overview and business model

• Clinical-stage product discovery company developing natural and engineered phage therapies targeting harmful bacteria in chronic diseases, such as diabetic foot infections.

• Utilizes proprietary BOLT platform for high-throughput screening, directed evolution, and synthetic biology to create phage cocktails and personalized therapies.

• Recent strategic shift to focus on bacteriophage-based therapeutics, particularly BX011 for diabetic foot infections, after discontinuing a Phase 2b trial for BX004 and dissolving its Israeli subsidiary.

Financial performance and metrics

• As of February 3, 2026, 1,593,516 shares of Common Stock were issued and outstanding prior to the offering.

• The offering could increase the outstanding shares by approximately 333.28%, causing substantial dilution to existing stockholders.

Use of proceeds and capital allocation

• Will not receive proceeds from the resale of shares by selling stockholders; proceeds from warrant exercises, if any, will be used for general corporate purposes.